Phaseline

Companies › Zenas BioPharma (USA)

Zenas BioPharma (USA): clinical trials, targets and expected readouts

2 active drug programs in 6 registered trials: 4 Phase 3, 2 Phase 2; Neurology, Hematology, Immunology, Other; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Obexelimab
B-lymphocyte antigen CD19 inhibitor; Low affinity immunoglobulin gamma Fc region receptor II-b inhibitor
CD19, FCGR2BPhase 3Warm Autoimmune Hemolytic Anemia; IgG4 Related Disease; Relapsing Multiple Sclerosis; Systemic Lupus ErythematosusDec 2026
Orelabrutinib
Tyrosine-protein kinase BTK inhibitor
BTKPhase 3Secondary Progressive Multiple Sclerosis; Multiple Sclerosis (MS) Primary ProgressiveJun 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06564311ObexelimabPhase 2Relapsing Multiple SclerosisNeurologyAug 2025
NCT05786573ObexelimabPhase 3Warm Autoimmune Hemolytic AnemiaHematologyJun 2026
NCT06559163ObexelimabPhase 2Systemic Lupus ErythematosusImmunologyDec 2026
NCT05662241ObexelimabPhase 3IgG4 Related DiseaseOtherFeb 2029
NCT07299019OrelabrutinibPhase 3Secondary Progressive Multiple SclerosisNeurologyJun 2030
NCT07067463OrelabrutinibPhase 3Multiple Sclerosis (MS) Primary ProgressiveNeurologyJun 2030

From the company's SEC filings

Cash and short-term investments of $647m on 2026-09-30; operating cash outflow about $256m a year; runway about 30 months at that burn, to Apr 2029; 2 of 4 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Regulatory dates the company has stated

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 6 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

BTK (1) CD19 (1) FCGR2B (1)

Companies with the same targets

Gilead Sciences Bristol-Myers Squibb Chongqing Precision Biotech AstraZeneca Sanofi Roche Allogene Therapeutics Miltenyi Biomedicine Merck & Co. (MSD) BeOne Medicines

Companies built like this

Cartesian Therapeutics COMPASS Pathways Immunovant Sciences Vor Biopharma Evommune

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.